Biotechnology, Pharmaceutical & Life Sciences IP Litigation

• Represented Apotex in litigation involving multiple patents associated with the treatment of overactive bladder with mirabegron (Myrbetriq®). (D. Del.)
• Represented Apotex in litigation involving three patents associated with the treatment of patients with relapsing multiple sclerosis using teriflunomide (Aubagio®). (D. Del.)
• Represented Mylan in litigation involving multiple patents associated with linaclotide (Linzess®) capsules, approved in adults for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation. (D. Del.)
• Represented Watson Laboratories Inc. in two separate PIV Hatch–Waxman litigations involving four patents related to compositions containing dronedarone (Multaq®), and the use thereof, for treatment of patients with atrial fibrillation. (D. Del.)
• Represented Mylan Pharmaceuticals Inc. in PIV Hatch–Waxman litigation involving DPP-IV inhibitors and metformin for the treatment of type 2 diabetes. (D.N.J.)
• Represented Actavis Laboratories Fl. Inc. in ANDA litigation involving extended-release oxycodone and acetaminophen tablets. (D.N.J.)
• Represented a multinational animal health company in patent litigation involving technology related to insecticidal combinations to control mammal fleas. (M.D. Ga.)
• Represented MiMedx as patentee/plaintiff in patent litigation against direct competitor Nutech Medical Inc. involving medical tissue graft technology. (N.D. Ala.)
• Represented patentee MiMedx in patent litigation involving two patents directed to human amniotic tissue wound grafts and related technologies. (N.D. Ala.)
• Represented Orient Pharma Co. Ltd. in ANDA litigation involving pitavastatin tablets. (N.D. Ill.)
• Represented Agila in Section 505(b)(2) Hatch–Waxman litigation involving two patents directed to an intravenous formulation of acetaminophen (Ofirmev®). (D. Del.)
• Represented Mylan in litigation involving multiple patents directed to treating schizophrenia, bipolar disorder, depression, and autism spectrum disorders with aripiprazole (Abilify®). (D.N.J.)
• Represented MiMedx in multiple patent litigations involving six patents directed to human amniotic human tissue wound grafts and related technologies. (N.D. Ga.; W.D. Tex.)
• Represented a multinational animal health company in a declaratory judgment patent infringement litigation involving technology related to recombinant protein animal vaccines. (D. Kan.)
• Represented a multinational animal health company in patent litigation involving technology related to flea and tick medicine. (M.D. Ga.)
• Represented a major life science company in a patent infringement investigation and related district court litigation involving folate nutraceutical products against a direct competitor. (E.D. Tex.)
• Represented a multinational animal health company in a series of patent litigations against a direct competitor involving technology related to flea and tick medicine. (M.D. Ga.)
• Represented a major life science company in patent litigation involving stereoisomers of methylfolate. (S.D.N.Y.)

Back to Top

Patent Trial and Appeal Board

• Represented a multinational animal health company in the following post grant and inter partes review proceedings:
  • PGR2022-00021 involving patent number 10,954,274, “Porcine circovirus type 3 immunogenic compositions and methods of making and using the same.”
  • PGR2020-00076 involving patent number 10,450,351, “Porcine circovirus type 3 immunogenic compositions and methods of making and using the same.”
  • IPR2019-00381 involving patent number 9,669,087, “Use of a PCV2 immunogenic composition for lessening clinical symptoms in pigs.”
  • IPR2019-00374 involving patent number 9,610,345, “Use of a PCV2 immunogenic composition for lessening clinical symptoms in pigs.”
  • IPR2018-01788 involving patent number 9,011,872, “PCV2 immunogenic compositions and methods of producing such compositions.”
  • IPR2018-01789 involving patent number 9,011,872 entitled “PCV2 immunogenic compositions and methods of producing such compositions.”
• Represented a generics and biosimilars pharmaceutical company in IPR2019-00865 involving patent number 9,795,604, “Methods of treating and preventing graft versus host disease.”
• Represented MiMedx Group Inc. in the following inter partes proceedings:
  • IPR2017-01220 involving patent number 8,709,494, “Placental tissue grafts.”
  • IPR2015-00669 involving patent number 8,323,701, “Placental tissue grafts.”
  • IPR2015-00664 involving patent number 8,372,437, “Placental tissue grafts.”
  • IPR2015-00420 involving patent number 8,597,687, “Methods for determining the orientation of a tissue graft.”
  • IPR2015-00320 involving patent number 8,709,494, “Placental tissue grafts.”
• Represented a multinational animal health companyin the following inter partes proceedings:
  • IPR2018-00919 involving patent number 8,008,001, “PCV-2 vaccine.”
  • IPR2016-00798 involving patent number 8,614,244, “Spot-on pesticide composition.”
  • IPR2015-00254 involving patent number 6,517,843, “Reduction of porcine circovirus-2 viral load with inactivated PCV-2.”
• Represented InnoPharma Licensing Inc. in the following inter partes proceedings:
  • IPR2016-00091 involving patent number 8,927,606, “Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid.”
  • IPR2016-00090 involving patent number 8,871,813, “Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid.”
  • IPR2016-00089 involving patent number 8,754,131, “Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid.”
  • IPR2015-00903 involving patent number 8,129,431, “Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid.”
  • IPR2015-00902 involving patent number 8,669,290, “Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid.”

Back to Top

International Trade Commission

• Represented Slmp LLC d/b/a StatLab Medical Products in an ITC investigation into swabs for collecting biological specimens. Certain Flocked Swabs, Products Containing Flocked Swabs, and Methods of Using Same, Inv. No. 337-TA-1279 (U.S.I.T.C.).
• Represented a major life science company in an ITC investigation into nutraceutical products. Certain Reduced Folate Nutraceutical Products and L-Methylfolate Raw Ingredients Used Therein, Inv. No. 337-TA-857 (U.S.I.T.C.).
• Represented Hygieia Health Co., Ltd. in an ITC investigation into glucosamine. Non-Shellfish Derived Glucosamine and Products Containing Same, Inv. No. 337-TA-668 (U.S.I.T.C.).

Back to Top

Appellate

• Represented a cardiovascular and cardiothoracic therapy leader in a patent appeal related to intravascular blood pumps. (Fed. Cir.)
• Represented an international medical device company in an appeal related to a patent license agreement involving vascular grafts. (9th Cir.)
• Represented International Refills Co., Ltd. in a patent appeal related to medical devices. (Fed. Cir.)
• Represented Provepharm Inc. in patent appeals related to diaminophenothiazinium compounds. (Fed. Cir.)
• Represented Mylan in a patent appeal related to DPP-IV inhibitors. (Fed. Cir.)
• Represented Mylan in a patent appeal related to antifolate combination therapies. (Fed. Cir.)
• Represented Actavis in patent appeals related to the drug dronedarone. (Fed. Cir.)
• Represented Mylan in a patent appeal related to antifolate combination therapies. (Fed. Cir.)
• Represented Mylan in a patent appeal related to granulated mesalamine. (Fed. Cir.)
• Represented Mylan in a patent appeal related to granulated mesalamine. (Fed. Cir.)
• Represented Mylan in patent appeals related to mesalazine controlled-release oral pharmaceutical compositions. (Fed. Cir.)
• Represented MiMedx in a patent appeal related to placental tissue grafts. (Fed. Cir.)
• Represented Actavis in a patent appeal related to benzofuran derivatives. (Fed. Cir.)
• Represented Mylan in a patent appeal related to milnacipran and the treatment of fibromyalgia. (Fed. Cir.)

Back to Top